The price of Vir Biotechnology Inc. (NASDAQ: VIR) closed at $23.52 in the last session, up 4.30% from day before closing price of $22.55. In other words, the price has increased by $+0.97 from its previous closing price. On the day, 1002147 shares were traded. VIR stock price reached its highest trading level at $23.83 during the session, while it also had its lowest trading level at $22.78.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Ratios:
We take a closer look at VIR’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.33 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.00. For the most recent quarter (mrq), Quick Ratio is recorded 4.90 and its Current Ratio is at 4.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on March 06, 2023, Upgraded its rating to Overweight and sets its target price to $34 from $35 previously.
On February 21, 2023, Goldman Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $41 to $53.
Morgan Stanley Upgraded its Underweight to Equal-Weight on January 27, 2023, whereas the target price for the stock was revised from $18 to $30.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 08 when SATO VICKI L sold 17,935 shares for $22.59 per share. The transaction valued at 405,062 led to the insider holds 1,327,324 shares of the business.
Friedl-Naderer Johanna sold 1,482 shares of VIR for $33,819 on Mar 03. The EVP & Chief Operating Officer now owns 148,518 shares after completing the transaction at $22.82 per share. On Mar 01, another insider, Sigal Charles Elliott, who serves as the Director of the company, bought 2,500 shares for $22.73 each. As a result, the insider paid 56,816 and bolstered with 10,000 shares of the company.
Valuation Measures:
As of this moment, Vir’s Price-to-Earnings (P/E) ratio for their current fiscal year is 6.17. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.88. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.98 while its Price-to-Book (P/B) ratio in mrq is 1.51.
Stock Price History:
Over the past 52 weeks, VIR has reached a high of $31.78, while it has fallen to a 52-week low of $18.05. The 50-Day Moving Average of the stock is 26.22, while the 200-Day Moving Average is calculated to be 25.26.
Shares Statistics:
According to the various share statistics, VIR traded on average about 988.10K shares per day over the past 3-months and 1.15M shares per day over the past 10 days. A total of 133.16M shares are outstanding, with a floating share count of 115.10M. Insiders hold about 1.70% of the company’s shares, while institutions hold 76.10% stake in the company. Shares short for VIR as of Jan 12, 2023 were 3.73M with a Short Ratio of 4.87M, compared to 3.8M on Dec 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 2.80% and a Short% of Float of 4.48%.
Earnings Estimates
The company has 8 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.39 for the current quarter, with a high estimate of $0.84 and a low estimate of -$1.2, while EPS last year was $3.92. The consensus estimate for the next quarter is -$0.57, with high estimates of -$0.53 and low estimates of -$0.61.
Analysts are recommending an EPS of between $5.44 and $3.46 for the fiscal current year, implying an average EPS of $4.27. EPS for the following year is -$2.21, with 7 analysts recommending between -$0.55 and -$4.06.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $97.3M. It ranges from a high estimate of $178.1M to a low estimate of $41.9M. As of the current estimate, Vir Biotechnology Inc.’s year-ago sales were $812.75M, an estimated decrease of -88.00% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $115.97M, a decrease of -90.60% less than the figure of -$88.00% in the same quarter last year. There is a high estimate of $220.3M for the next quarter, whereas the lowest estimate is $66.6M.
A total of 8 analysts have provided revenue estimates for VIR’s current fiscal year. The highest revenue estimate was $1.9B, while the lowest revenue estimate was $1.54B, resulting in an average revenue estimate of $1.7B. In the same quarter a year ago, actual revenue was $1.1B, up 55.40% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $406.5M in the next fiscal year. The high estimate is $776.55M and the low estimate is $127.9M. The average revenue growth estimate for next year is down -76.10% from the average revenue estimate for this year.
